Stanford Neurooncologist Reena Thomas Receives CIRM Award of Nearly $12 Million for Immunotherapy Research; Work Will Involve Phase 1 Clinical Trial of CAR-T Cells to Treat Glioblastoma

The California Institute for Regenerative Medicine (CIRM) has awarded nearly $12 million to Reena Thomas, MD, PhD, Clinical Associate Professor of Neurology and The Neurological Sciences, for a phase 1 clinical trial to assess the safety of a CAR-T cell immunotherapy for glioblastoma multiforme, the most common malignant primary brain tumor in adults.